FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205653224> ?p ?o ?g. }

• W4205653224 endingPage "157" @default.
• W4205653224 startingPage "155" @default.
• W4205653224 abstract "To the Editor: We read, with great interest, the studies by Kollman et al1Kollman N. Bass J. Generalized familial benign chronic pemphigus (Hailey-Hailey disease) treated successfully with low-dose naltrexone.JAAD Case Rep. 2018; 4: 725-727Abstract Full Text Full Text PDF PubMed Scopus (15) Google Scholar and Alajmi et al,2Alajmi A. Jfri A. Lovett A. Hailey-Hailey disease treated successfully with naltrexone and magnesium.JAAD Case Rep. 2019; 5: 760-762Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar which reported the efficacy of different dosages of low-dose naltrexone (LDN) in patients with Hailey-Hailey disease (HHD). Several studies have reported the efficacy of LDN in HHD over the past decade.1Kollman N. Bass J. Generalized familial benign chronic pemphigus (Hailey-Hailey disease) treated successfully with low-dose naltrexone.JAAD Case Rep. 2018; 4: 725-727Abstract Full Text Full Text PDF PubMed Scopus (15) Google Scholar, 2Alajmi A. Jfri A. Lovett A. Hailey-Hailey disease treated successfully with naltrexone and magnesium.JAAD Case Rep. 2019; 5: 760-762Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar, 3Albers L.N. Arbiser J.L. Feldman R.J. Treatment of Hailey-Hailey disease with low-dose naltrexone.JAMA Dermatol. 2017; 153: 1018-1020Crossref PubMed Scopus (42) Google Scholar There is no clear cutoff for LDN dosage, however. Interestingly, in Kollman et al,1Kollman N. Bass J. Generalized familial benign chronic pemphigus (Hailey-Hailey disease) treated successfully with low-dose naltrexone.JAAD Case Rep. 2018; 4: 725-727Abstract Full Text Full Text PDF PubMed Scopus (15) Google Scholar satisfactory 95% skin improvement was only achieved with 9-mg daily doses of naltrexone. Other studies have reported 2 patients successfully treated with 12.5 mg and 50 mg of naltrexone.4Jasans-Barceló M. Curman P. Hagströmer L. Wikstrom J.D. Sairafi D. Improvement of Hailey–Hailey disease with low-dose naltrexone.Br J Dermatol. 2020; 182: 1500-1502https://doi.org/10.1111/bjd.18861Crossref PubMed Scopus (5) Google Scholar,5Cao S. Lilly E. Chen S.T. Variable response to naltrexone in patients with Hailey-Hailey disease.JAMA Dermatol. 2018; 154: 362-363Crossref PubMed Scopus (24) Google Scholar We believe that the importance of dosage for naltrexone in HHD should be emphasized, and we have observed the efficacy of medium-dose naltrexone (MDN) in 2 patients. The first patient was a 112-kg woman in her 30s with a 10-year history of HHD poorly responsive to 0.05% topical clobetasol propionate, several courses of antibiotics during exacerbations, and a 2-month treatment with 20 mg methotrexate weekly. She consulted for disease exacerbation, with 15% body surface area (BSA) involvement associated with a Staphylococcus aureus superinfection. The methotrexate was stopped, and she was given a 5-day course of antibiotic treatment with clavulanic acid and amoxicillin and naltrexone at 12.5 mg per day (MDN), associated with 0.05% clobetasol propionate. After 2 weeks, her wounds began to heal. Three months later, she presented a complete response, which was sustained at 14 months (Fig 1), and she had no adverse reactions. The second patient was a woman in her 50s with a 20-year history of HHD. The state of her disease was persistent, with no interspersed remission periods in the previous 6 years despite topical corticosteroids and tacrolimus and several courses of systemic antibiotics. At admission, she weighed 52 kg and had 10% BSA involvement associated with a documented S aureus superinfection. Local skin treatment, 1 g pristinamycine 3 times daily, and 12.5 mg naltrexone daily were initiated. After 8 days of treatment, her wounds were almost healed, and she achieved complete remission 6 weeks after MDN initiation. At 10 months, she presented a sustained partial remission, with the exception of a discrete erythema in the inguinal and groin creases (Fig 2). Regarding safety, she only reported loose stools. The response to naltrexone seems to be heterogeneous according to different dosage regimens and wound severities. Given the effectiveness of MDN reported in the literature and the extended BSA involvement and weight-to-dosage ratio in our first obese patient, we chose a treatment of 12.5 mg MDN (0.1 mg/kg) rather than LDN. Her rapid, complete response prompted us to initiate the same dosage in our second patient, who also achieved a sustained and persistent response. Our hypothesis is that a higher dosage may be needed for greater BSA involvement in conjunction with severe inflammation. We also surmise that the dosage should be related to weight and suggest that MDN in patients with obesity could correspond to LDN in nonobese patients. None disclosed." @default.
• W4205653224 created "2022-01-25" @default.
• W4205653224 creator A5004047588 @default.
• W4205653224 creator A5009285651 @default.
• W4205653224 creator A5012521997 @default.
• W4205653224 creator A5035118371 @default.
• W4205653224 creator A5048107848 @default.
• W4205653224 creator A5076126022 @default.
• W4205653224 creator A5079316525 @default.
• W4205653224 date "2022-05-01" @default.
• W4205653224 modified "2023-09-30" @default.
• W4205653224 title "The importance of dosage for naltrexone treatment in Hailey-Hailey disease" @default.
• W4205653224 cites W2740158059 @default.
• W4205653224 cites W2787011167 @default.
• W4205653224 cites W2885870185 @default.
• W4205653224 cites W2970880088 @default.
• W4205653224 cites W2998739300 @default.
• W4205653224 doi "https://doi.org/10.1016/j.jdcr.2021.11.036" @default.
• W4205653224 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35519796" @default.
• W4205653224 hasPublicationYear "2022" @default.
• W4205653224 type Work @default.
• W4205653224 citedByCount "0" @default.
• W4205653224 crossrefType "journal-article" @default.
• W4205653224 hasAuthorship W4205653224A5004047588 @default.
• W4205653224 hasAuthorship W4205653224A5009285651 @default.
• W4205653224 hasAuthorship W4205653224A5012521997 @default.
• W4205653224 hasAuthorship W4205653224A5035118371 @default.
• W4205653224 hasAuthorship W4205653224A5048107848 @default.
• W4205653224 hasAuthorship W4205653224A5076126022 @default.
• W4205653224 hasAuthorship W4205653224A5079316525 @default.
• W4205653224 hasBestOaLocation W42056532241 @default.
• W4205653224 hasConcept C126322002 @default.
• W4205653224 hasConcept C16005928 @default.
• W4205653224 hasConcept C170493617 @default.
• W4205653224 hasConcept C2777972943 @default.
• W4205653224 hasConcept C2778494947 @default.
• W4205653224 hasConcept C2779134260 @default.
• W4205653224 hasConcept C2781063702 @default.
• W4205653224 hasConcept C2781327288 @default.
• W4205653224 hasConcept C71924100 @default.
• W4205653224 hasConceptScore W4205653224C126322002 @default.
• W4205653224 hasConceptScore W4205653224C16005928 @default.
• W4205653224 hasConceptScore W4205653224C170493617 @default.
• W4205653224 hasConceptScore W4205653224C2777972943 @default.
• W4205653224 hasConceptScore W4205653224C2778494947 @default.
• W4205653224 hasConceptScore W4205653224C2779134260 @default.
• W4205653224 hasConceptScore W4205653224C2781063702 @default.
• W4205653224 hasConceptScore W4205653224C2781327288 @default.
• W4205653224 hasConceptScore W4205653224C71924100 @default.
• W4205653224 hasLocation W42056532241 @default.
• W4205653224 hasLocation W42056532242 @default.
• W4205653224 hasLocation W42056532243 @default.
• W4205653224 hasOpenAccess W4205653224 @default.
• W4205653224 hasPrimaryLocation W42056532241 @default.
• W4205653224 hasRelatedWork W1549495679 @default.
• W4205653224 hasRelatedWork W2096688446 @default.
• W4205653224 hasRelatedWork W2202073062 @default.
• W4205653224 hasRelatedWork W2288502042 @default.
• W4205653224 hasRelatedWork W2412424067 @default.
• W4205653224 hasRelatedWork W2412601269 @default.
• W4205653224 hasRelatedWork W2413799153 @default.
• W4205653224 hasRelatedWork W2421565422 @default.
• W4205653224 hasRelatedWork W2470794159 @default.
• W4205653224 hasRelatedWork W2885870185 @default.
• W4205653224 hasVolume "23" @default.
• W4205653224 isParatext "false" @default.
• W4205653224 isRetracted "false" @default.
• W4205653224 workType "article" @default.